CytomX(CTMX) - 2023 Q4 - Annual Results

Exhibit 99.1 CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., March 11, 2024 – CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today reported full year 2023 financial results and provided a business update. "2023 was a year of sustained execution across our pipeline, highlighted by the continued progress of CX-904 in Phase 1 dose escalation and the parallel advancement of CX-2051 and ...